Rangaswamy Govindarajan, M.D. | UAMS Health

Dr. Rangaswamy Govindarajan

Claim this profile

John L McClellan Memorial Veterans Hospital

Studies Lung Cancer
Studies Prostate Cancer
10 reported clinical trials
42 drugs studied

Area of expertise

1Lung Cancer
Rangaswamy Govindarajan has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
ALK positive
Stage I
2Prostate Cancer
Rangaswamy Govindarajan has run 2 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
John L McClellan Memorial Veterans Hospital
Image of trial facility.
University Of Arkansas For Medical Sciences

Clinical Trials Rangaswamy Govindarajan is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Rangaswamy Govindarajan

Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Rangaswamy Govindarajan has experience with
  • Crizotinib
  • Abiraterone Acetate
  • Cabazitaxel
  • Antiandrogen Therapy
  • Prednisone
  • Ulixertinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rangaswamy Govindarajan specialize in?
Is Rangaswamy Govindarajan currently recruiting for clinical trials?
Are there any treatments that Rangaswamy Govindarajan has studied deeply?
What is the best way to schedule an appointment with Rangaswamy Govindarajan?
What is the office address of Rangaswamy Govindarajan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security